Avadel pharmaceuticals to present new data on lumryz™ (sodium oxybate) for extended-release oral suspension at world sleep 2025

– 17 abstracts accepted, including one oral presentation – – data from the refresh real-world study highlight efficacy of once-nightly sodium oxybate when switching from twice-nightly oxybates – – refresh study also highlights efficacy in those who were new to oxybate or returning to oxybate after discontinuing twice-nightly oxybate – dublin, sept. 05, 2025 (globe newswire) -- avadel pharmaceuticals plc (nasdaq: avdl), a biopharmaceutical company focused on transforming medicines to transform lives, today announced that new data supporting the use of lumryz as a narcolepsy treatment will be presented in one oral presentation and 16 posters at world sleep 2025, taking place september 5-10, in singapore.
AVDL Ratings Summary
AVDL Quant Ranking